Akums Drugs Posts Robust Q1 FY27 Results, Reporting 13.9% Revenue Growth and Strong CDMO Performance
New Delhi, August 2026: Akums Drugs and Pharmaceuticals Ltd., a leading Contract Development and Manufacturing Organization (CDMO) in India, announced its consolidated financial results for the quarter ended June 30, 2026. The company reported healthy increases across revenue, operating profitability, and PAT, attributing the growth to continued momentum in its CDMO business, improved operating performance, and stable customer demand.The company recorded operating revenue of ₹1,167 crore in Q1 FY27, marking a 13.9% year-on-year increase compared to the ₹1,024 crore reported in Q1 FY26. EBITDA rose by 35.4% year-on-year, reaching ₹175 crore. This increase saw the EBITDA margin improve to 15.0%, up from 12.6%. Profit After Tax (PAT) stood at ₹101 crore, up from ₹65 crore in the corresponding quarter last year. The PAT margin also improved to 8.4% from 6.2%.
The CDMO segment was highlighted as a key driver of growth during the quarter. CDMO revenue increased to ₹964 crore, up from ₹813 crore in Q1 FY26. Correspondingly, CDMO EBITDA grew 36.8% year-on-year to ₹163 crore, supported by continued volume growth and improvements in API prices.
"FY27 has begun on a strong and encouraging note," said Mr. Sanjeev Jain, Managing Director. "The consistent performance of CDMO showcases a healthy demand environment as well as our clients' trust in Akums as the preferred manufacturing partner."
Mr. Sandeep Jain, Managing Director, further stated: "We remain focused on strengthening our CDMO leadership, scaling high-value capabilities, and driving operational excellence. Backed by a strong pipeline and prudent capital allocation, we are well-positioned to deliver sustainable growth in the years ahead."
Consolidated Financial Performance Snapshot
The detailed consolidated financial results across the quarters were as follows:| Particulars (Rs Cr) | Q1 FY 27 | Q4 FY 26 | Q1 FY 26 |
|---|---|---|---|
| Revenue | 1,167 | 1,158 | 1,024 |
| Cost of goods sold | 645 | 660 | 582 |
| Employee Cost | 201 | 199 | 176 |
| Other Expenses | 145 | 147 | 137 |
| EBITDA | 175 | 152 | 129 |
| EBITDA Margin | 15.0% | 13.1% | 12.6% |
| PAT | 101 | 81 | 65 |
| PAT Margin | 8.4% | 6.8% | 6.2% |
AKUMS Stock Price Movement
On Friday, Akums Drugs and Pharmaceuticals Limited shares surged, gaining 4.9% to settle at ₹697.45. The stock saw robust activity, recording a traded volume of 637,075 during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.